Lecanemab-irmb (Leqembi) is given by intravenous infusion every two weeks for 18 months, after which it may be administered every two or four weeks.
Notes on verification
Confirmed by FDA prescribing information, Eisai's official site, and independent medical news source (Practical Neurology).
Sources
- Dementia - Diagnosis and treatment (mayoclinic.org)
- https://www.drugs.com/pro/leqembi.html (drugs.com)
- https://practicalneurology.com/news/leqembi-maintenance-dosing-approved-by-the-fda/2473771/ (practicalneurology.com)
- https://www.leqembi.com/leqembi-after-18-months (leqembi.com)